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Abstract
Introduction Non-dystrophic myotonias (NDM) are heterogeneous diseases caused by mutations in CLCN1 and SCN4A. 
The study aimed to describe the clinical and genetic spectrum of NDM in a large German cohort.
Methods We retrospectively identified all patients with genetically confirmed NDM diagnosed in our center. The follow-
ing data were analyzed: demographics, family history, muscular features, cardiac involvement, CK, EMG, genotype, other 
tested genes, treatment perceived efficacy.
Results 70 patients (age 40.2 years ± 14.9; 52.8% males) were included in our study (48 NDM-CLCN1, 22 NDM-SCN4A). 
The most frequent presenting symptoms were myotonia (NDM-CLCN1 83.3%, NDM-SCN4A 72.2%) and myalgia (NDM-
CLCN1 57.4%, NDM-SCN4A 52.6%). Besides a more prominent facial involvement in NDM-SCN4A and cold-sensitivity 
in NDM-CLCN1, no other significant differences were observed between groups. Cardiac arrhythmia or conduction defects 
were documented in sixNDM-CLCN1 patients (three of them requiring a pacemaker) and one patient with NDM-SCN4A. 
CK was normal in 40% of patients. Myotonic runs in EMG were detected in 89.1% of CLCN1 and 78.9% of SCN4A. 50% 
of NDM-CLCN1 patients had the classic c.2680C>T (p.Arg894*) mutation. 12 new genetic variants are reported. About 
50% of patients were not taking any anti-myotonic drug at the last follow-up. The anti-myotonic drugs with the best patient’s 
perceived efficacy were mexiletine and lamotrigine.
Conclusion This study highlights the relevant clinical overlap between NDM-CLCN1 and NDM-SCN4A patients and war-
rants the use of early and broad genetic investigation for the precise identification of the NDM subtype. Besides the clinical 
and genetic heterogeneity, the limited response to current anti-myotonic drugs constitutes a continuing challenge.
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Introduction
Non-dystrophic myotonias (NDM) are rare hereditary neu-
romuscular diseases caused predominantly by mutations in 
CLCN1 or SCN4A, respectively coding for the voltage-gated 
muscle channels ClC-1 and NaV1.4 [1, 2]. More than 150 
CLCN1 and at least 100 SCN4A myotonia-associated gene 
variants are currently known [3]. The common feature of 
these diseases is the altered electrical excitability of the 
muscular membrane [4]. In most cases, mutations lead to 
hyperexcitability, which manifests itself clinically as delayed 
muscle relaxation after voluntary contraction, also called 
myotonia [5–7]. The pathophysiological mechanism of myo-
tonia is mainly related to reduced activity of the chloride 
channels and consequently reduced chloride conductivity 
in CLCN1, whereas in SCN4A-myotonias it is caused by an 
impaired inactivation of the NaV1.4 channels [5, 8].
CLCN1-myotonias, also known as myotonia congenita 
(MC), are to be distinguished into the autosomal dominant 
type Thomsen (TMC) and the autosomal recessive type 
Becker (BMC), related to the type of mutation. Although 
some CLCN1 mutations may be inherited both as autosomal 
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recessive and dominant, making it difficult in some patients 
to classify them without a detailed genetic and clinical study 
of other family members. SCN4A-myotonias include par-
amyotonia congenita Eulenburg (PMC), potassium aggra-
vated myotonia (PAM), and hyperkalemic periodic paralysis 
with myotonia (hyperPP) [9].
The phenotype of NDMs involves almost exclusively the 
skeletal muscle and, differently from dystrophic myotonias 
(DM), no relevant extra-muscular involvement has been 
described so far. The onset of symptoms is usually described 
in the first to the second decade of life; the lead symptom 
is myotonia, which is however often described by patients 
as stiffness, occurring especially during suddenly initiated 
movements after a resting period [9]. Otherwise, prolonged 
depolarization may temporarily reduce the excitability of 
the muscle membrane, causing transient weakness or peri-
odic paralysis [8]. Significant clinical overlap exists between 
CLCN1 and SCN4A myotonias. Nevertheless, some features 
can help to distinguish both forms. CLCN1-myotonias are 
usually characterized by a warm-up phenomenon, worsening 
of myotonia under low temperature environment, and more 
prominent myotonia at lower limbs. Temporary weakness 
and segmental muscle hypertrophy occur mainly in patients 
with BMC [2, 10–12]. On the other hand, patients with PMC 
typically show worsening of their myotonia after repeti-
tive movements, and under low-temperature environment. 
The SCN4A associated myotonia commonly involves the 
facial muscles with eyelid myotonia; the muscle weakness 
can occur more frequently and may persist longer than in 
CLCN1 patients [2, 11]. In addition to medical history and 
neurological examination, the detection of myotonic runs 
(MR) in electromyography (EMG) is an important hallmark 
for suspecting a NDM. Specific EMG protocols (repetitive 
stimulation, the “short” and “long” exercise tests, and the 
provocative cold test) even allow the differentiation between 
chloride and sodium channel myotonia with relatively high 
sensitivity and specificity [13]. Nevertheless, the precise 
diagnosis needs genetic analysis.
Up-to-date, no causal treatments are available for NDM 
but several drugs can be adopted for the symptomatic treat-
ment of myotonia in the attempt to improve patients’ quality 
of life [2]. Presently, anti-myotonic drugs with the highest 
level of evidence concerning efficacy are mexiletine and 
lamotrigine [14–16]. Many other substances such as car-
bamazepine, flecainide, phenytoin, propafenone, or more 
recently cannabinoids are also being used [11, 17]. Unfor-
tunately, many patients still do not report sufficient improve-
ment of their core symptom myotonia.
Due to the rarity of these diseases, only a few large 
cohorts (n > 50) have been described in the literature to this 
date (Table 1). A description of a large genetically confirmed 
cohort of German NDM patients dates back to the year 1993 
[18].
The aim of this study was to investigate the clinical 
features of a large cohort of German patients with NDM, 
highlighting some diagnostic and therapeutic challenges 




This is a monocentric, retrospective study, performed at 
the Friedrich-Baur-Institute, Munich, Germany. We have 
included patients of all ages that, according to our insti-
tutional database of patient records, had a genetically con-
firmed diagnosis of NDM. If new genetic variants were 
detected, their pathogenicity was evaluated considering 
the presence of positive family history, documented typical 
clinical signs or symptoms of NDM, and the presence of 
myotonic runs in EMG. The database search refers to data 
archived between the years 1994 to 2019. Additional clinical 
data were obtained by additionally reviewing paper records 
of the identified patients.
Methods
The following data were collected and analyzed: demo-
graphics, age at onset, family history, first symptom, symp-
toms present during disease progression (myotonia, weak-
ness, muscle hypertrophy and atrophy, myalgia, cramps, 
dysphagia, dysphonia), symptoms at the last follow-up visit, 
presence of any type of cardiac involvement, creatine kinase 
(CK), EMG, genetic results including previously tested 
genes, diagnostic delay (time between the onset of symptoms 
and the genetic diagnosis), past and current anti-myotonic 
medications with patients perceived efficacy.
For disease onset, either the exact year or the develop-
ment stage (e.g., birth, infancy, childhood…) were collected 
according to the information available from patient’ records. 
The age groups were determined as follows: < 1 year as 
infant, 1–9  years as child, 10–17  years as adolescent, 
18–35 years as young adult, 36–55 years as middle-aged 
adult, and > 55 years as old adult [19, 20]. We combined 
family history, clinical features, EMG, and genetic results 
to classify patients with CLCN1 mutations in either Becker 
(BMC) or Thomsen myotonia (TMC).
The following cardiac abnormalities were included: con-
duction defects, cardiac arrhythmia, or cardiomyopathies.
Due to various reference values of CK through the years, 
all values were expressed as the percentage of normal value 
and converted into absolute values considering gender-spe-
cific reference values of our laboratory. The CK is reported 
referring to the highest CK values found. The EMG data 
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refer to the first documented EMG. The efficacy of anti-
myotonic treatment was semiquantitatively evaluated as 
1 = excellent, 2 = good, or 3 = poor according to the patient 
evaluation reported in patient records by the treating doctor. 
The follow-up period was calculated between the first and 
the last recorded follow-up visit.
Statistic analysis
All statistical analyses were performed with IBM SPSS Sta-
tistics (Version 25.0.0.1). The normality of variables was 
assessed by Shapiro–Wilk-test. Descriptive analysis included 
mean ± standard deviation (SD) or median and interquar-
tile range (IQR), as appropriate, for continuous variables. 
Frequencies were calculated for categorical variables. For 
normally distributed continuous variables unpaired Stu-
dent’s tests were used to assess differences between groups, 
while for non-normally distributed continuous variables the 
Mann–Whitney U test was used. χ2 or Fisher’s exact test was 
used to compare frequencies. All hypothesis tests conducted 
were two-tailed. A p value < 0.05 was considered significant.
Results
Clinical features
We identified 76 patients with clinical suspicion of NDM 
and genetic results. Six patients were excluded due to incon-
clusive genetic results or lack of sufficient clinical data. We 
enrolled 70 patients (64 families): 48 (68.5%) patients had a 
diagnosis of CLCN1-myotonia and 22 (31.4%) of SCN4A-
myotonia. The mean age was 40.2 ± 14.9 years, with no 
significant difference between the two groups. Thirty-seven 
patients were male (52.8%). No gender differences were 
identified for any of the analyzed variables. A detailed sum-
mary of the core clinical features of this cohort and the 
differences between NDM-CLCN1 and NDM-SCN4A are 
shown in Table 2 and Fig. 1.
The onset of symptoms was reported mostly in childhood 
(39.6%) or adolescence (28.5%) and no patient reported 
the onset of symptoms after the fifth decade. No statisti-
cally significant difference was observed in age at onset 
between NDM-CLCN1 and NDM-SCN4A. The most fre-
quent symptom at onset was myotonia (74.1%), followed by 
myalgia (16.1%) and muscle weakness (14.5%). Myotonia 
at onset was more frequent in patients with CLCN1-myoto-
nia (85.7%) than in patients with SCN4A-myotonia (50%) 
(p = 0.003); periodic paralysis was only reported in patients 
with SCN4A-myotonia (20%) (p = 0.008).
At the last documented follow-up visit, the majority of 
patients presented myotonia (NDM-CLCN1 83.3%, NDM-
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Table 2  Demographics and clinical features of this cohort of patients





Age 70 40.91 ± 15.05 years 38.70 ± 14.82 years 0.57 47.7 ± 13.9 46.8 ± 16.08 40 0.91
Gender 70 52.08% (m), 47.92% 
(f)
54.55% (m), 45.45% 
(f)
0.85 58.3% (m) 53.6% (m) 40 0.82
Family history 66 50.0% pos., 50.0% 
neg
70.0% pos., 30.0% 
neg
0.11 – –
Mean follow-up 70 4.83 ± 6.74 years 3.20 ± 4.15 years 0.92 7.3 ± 6.45 3.2 ± 6.9 40 0.08*
Age at onset 39 13.50 (10.00–29.50) 14.00 (10.00–40.00) 0.54 19.2 (10–37.5) 16.9 (8.7–25.5) 23 0.66
Symptoms at onset: 34
 Myotonia 62 85.7% 50% 0.003* 90.9% 86.9% 0.47
 Myalgia 62 19.0% 10.0% 0.48 36.3% 4.3% 0.029*
 Weakness/paresis 62 11.9% 20.0% 0.45 18% 13% 0.52
 Cramps 62 9.5% 10.0% 1.00 – –
 Periodic paralysis 62 0.0% 20.0% 0.009* – –
Symptoms during follow-up 40
 Myotonia 66 83.3% 72.2% 0.32 66.6% 92.8% 0.048*
 Paresis 66 23.4% 5.3% 0.16 25% 25.9% 1
 Myalgia 66 57.4% 52.6% 0.72 66.6% 48.1% 0.32
 Cramps 66 40.4% 36.8% 0.79 – –
 Muscle hypertrophy 68 43.8% 30.0% 0.42 16.6% 42.8% 0.15
 Dysphagia 66 10.6% 5.3% 0.66 – –
 Dysphonia 66 6.4% 10.5% 0.62 – –
 Muscle atrophy 67 6.3% 0.0% 0.55 – –
Myotonia localisation 35
 Arms 46 88.6% 81.8% 0.56 100.00% 86.3% 0.37
 Legs 46 57.1% 45.5% 0.73 25% 68.18% 0.045*
 Face 46 42.9% 81.8% 0.024* 25% 50% 0.4
Myotonia characteristics 39
 Warm-up 62 57.4% 40.0% 0.24 50% 66% 0.47
 Grip myotonia 62 72.3% 66.7% 0.75 58.3% 74% 0.45
 Percussion myo-
tonia
62 68.1% 66.7% 1.00 75% 77.7% 1
Triggers 21
 Cold 41 89.3% 46.2% 0.005* 88.8% 100% 0.42
 Psychological stress 41 14.3% 7.7% 1.00 – –
 Occurrence of infec-
tions
41 0.0% 7.7% 0.32 – –
 Exercise 41 3.6% 0.0% 1.00 0% 6.2% 0.58
 Alcohol consump-
tion
41 3.6% 0.0% 1.00 – –




38 19% 11.1% 0.31 18.18% 44.44% 35 0.23
Diagnostic assessments 38
 Diagnostic delay 37 17.23 ± 11.93 years 15.27 ± 13.47 years 0.66 18.5 ± 9.7 17.8 ± 12.3 0.88
 Elevated CK 66 40.5% 38.1% 1.00 58.82% 60.00% 0.93










 Journal of Neurology
1 3
muscle weakness at their final neurological examination 
(NDM-CLCN1 23.4%, NDM-SCN4A 5.2%, p = 0.15). 
We could not find any statistically significant changes of 
manual muscle testing between the first and last examina-
tions (p = 0.184). The distribution of myotonia is reported 
in Table 2, facial involvement was significantly more fre-
quent in patients with SCN4A-myotonia (81.8% vs. 42.8%, 
p = 0.024). Cold temperature environment was the most 
common trigger for myotonia in all patients (75.61%), being 
however more frequently reported as a factor triggering or 
worsening symptoms from NDM-CLCN1 patients (89.2% 
vs. 46.1%, p = 0.005).
More than half of the patients reported myalgia during 
the disease course (NDM-CLCN1 57.4%, NDM-SCN4A 
52.6%, p = 0.72). Additionally, about 30–40% of patients 
reported muscle cramps with no significant differences 
between both types. Dysphagia and dysphonia were only 
rarely reported and mostly mild. Muscle hypertrophy 
was documented in both subtypes (NDM-CLCN1 43.7%, 
NDM-SCN4A 30%, p = 0.41), whereas muscle atrophy 
was only documented in a few NDM-CLCN1-patients 
(6.2%).
In the NDM-CLCN1 cohort, we classified 28 patients 
as BMC, 12 patients as TMC and in 8 cases it was not pos-
sible to clearly classify them as BMC or TMC. Comparing 
the features of BMC and TMC we found significant differ-
ences only as regards the presence of myalgia (more com-
mon in TMC), the presence of myotonia (more prevalent in 
BMC), and the distribution of myotonia, more frequently 
occurring in the legs of BMC patients (Table 2). Cardiac 
involvement was reported in six patients with NDM-
CLCN1 and one patient with NDM-SCN4A (Table 2). A 
detailed description of the cardiac pathologies is reported 
in Table 3. Six NDM-CLCN1 patients had relevant cardiac 
arrhythmias, in one with an early onset before age 45. Of 
these, three required pacemaker implantation.
*Statistically significant
Table 2  (continued)






 Myotonic runs 65 89.1% 78.9% 0.43 90.9% 100% 0.29
 Complex-repetitive 
discharges




65 13.0% 15.8% 0.71
Fig. 1  Comparison of symp-
toms in patients with NDM-
CLCN1 and NDM-SCN4A. 
*Statistically significant; filled: 
CLCN1; Dotted: SCN4A—(cre-
ated with Excel)
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Diagnostic assessments
The family history was positive in 56% of patients (50% 
NDM-CLCN1, 70% NDM-SCN4A patients). The mean 
diagnostic delay was 16.6 ± 12.2 years, without significant 
difference between both types or between patients with 
or without positive family history for myotonia. Further-
more, there was no significant difference in diagnostic delay 
between patients who were genetically tested after the year 
2010 (16 ± 11.9 years) and those before (19.1 ± 14.2 years) 
(p = 0.55).
40.5% of NDM-CLCN1 and 38.1% of NDM-SCN4A 
patients had normal CK values. In patients with elevated 
CK, the CK was on average 2–3 times upper normal limit 
with no relevant differences in both groups (median and IQR 
in NDM-CLCN1: 286.0 U/L, 226.5–467.7 U/L; median and 
IQR in NDM-SCN4A: 373.7 U/L, 213.4–1106.8 U/L).
The time between the onset of the disease and the perfor-
mance of the first EMG was on average 12.6 ± 10.7 years, 
with no significant differences between NDM-CLCN1 and 
NDM-SCN4A (14.2 ± 11.4 years for NDM-CLCN1 and 
8.7 ± 7.9 years in NDM-SCN4A; p = 0.152). EMG was 
normal in only 7.7% of the patients. Myotonic runs were 
detected in 86.2% of patients in their first documented EMG, 
other forms of pathological spontaneous activity as fibrilla-
tion potentials and pseudo-myotonic runs were present in 
18.5% of the patients.
A genetic confirmation was obtained in all patients. In 
24/70 no additional genes were tested before reaching the 
correct diagnosis (Supplementary Table 1). In the remain-
ing 46/70 patients, a tandem analysis of SCN4A and CLCN1 
was performed in 15.2% and next generation sequencing 
techniques were adopted in 58.9% of cases. In addition to 
other genes responsible for NDM, the most common dif-
ferential diagnosis was myotonic dystrophy, investigated in 
47.1% of patients.
The genotype of all patients is shown in Table 4. Half 
of NDM-CLCN1-myotonia patients (n = 24) had at least 
one heterozygous c.2680C>T mutation. The most com-
mon mutations in SCN4A were the c.3917G>T (n = 5), c. 
1333G>A (n = 4) and c.2111C>T (n = 3). A total of 12 new 
genetic variants could be identified (highlighted in bold in 
Table 3). Newly identified mutations included frameshift, 
in-frame, missense, and splice-site mutations. The patients 
with novel variants did not show peculiar clinical features 
different from those of other patients with known CLCN1 
or SCN4A mutations.
Treatment
The mean follow-up duration for treatment was 4.3 ± 6 years, 
with no significant differences between patients with NDM-
CLCN1 or NDM-SCN4A (p = 0.92). From the review of 
all patients’ records, 13.3% of patients have never taken an 
anti-myotonic drug (11.4% of CLCN1 and 20% of SCN4A, 
p = 0.6). At the last follow-up visit, 48.9% of patients (44.7% 
of NDM-CLCN1, 63.6% NDM-SCN4A) were not taking 
any anti-myotonic medication, either because the symp-
toms’ burden was too low or because of the low efficacy or 
side effects of the drugs tested. All patients being treated 
with anti-myotonic drugs (51%) received a monotherapy. 
On average, two different anti-myotonic drugs were tested 
in the past (range 1–5). A list of the reported medications 
Table 3  Cardiac involvement
Bold = cases of interest
AV-Block atrioventricular block
Pt. ID Gender Age NDM Onset of car-
diac involve-
ment
Cardiac involvement Mutation 1 Mutation 2
8 M 56 CLCN1 54 Complete right bundle branch 
block
c.2680C>T (p.Arg894*) –
10 F 48 CLCN1 45 Cardiac arrhythmia c.870C>G (p.Ile290Met) –
17 M 68 SCN4A Not known Mild cardiac arrhythmia c.1333G>A (p.Val445Met) –
29 F 78 CLCN1 Not known Global heart failure and pace-
maker implantation unknown 
cause
c.2680C>T (p.Arg894*) c. 1238 T>G (p.Phe413Cys)
32 M 56 CLCN1 Not known Cardiac arrhythmia, AV-block I°, 
incomplete right bundle branch 
block
c.2680C>T (p.Arg894*) c.696G>A (p.Glu232Glu)
41 F 54 CLCN1 50 AV-block III°, pacemaker 
implantation
c.313C>T (p.Arg105Cys) c.501C>G (p.Phe167Leu)
71 F 40 CLCN1 30 AV-block II° and syncope, pace-
maker implantation
c.1649C>G (p.Thr550Arg) c.1649C>G (p.Thr550Arg)
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Table 4  Mutational spectrum
Pt. ID Gene Inheritance in 
the family*
Mutation 1 Mutation 1 Mutation 2 Mutation 2
1 CLCN1 AR c.407A>G p. Asp136Gly n.f n.f
3 CLCN1 AR c.1437_1450del p.Pro480Hisfs*24 c.2422_2427dup p.Glu808_Gln809dup
4 CLCN1 AD c.2680C>T p.Arg894* c.2680C>T p.Arg894*
5 CLCN1 AD/AR c.937G>A p.Ala313Thr c.2680C>T p.Arg894*
6 CLCN1 AR c.1437_1450del p.Pro480Hisfs*24 c.2680C>T p.Arg894*
8 CLCN1 AD c.2680C>T p.Arg894*
9 CLCN1 AR c.1444G>A p. Gly482Arg n.f n.f
10 CLCN1 AD c.870C>G p.Ile290Met
12 CLCN1 AR c.2680C>T p.Arg894* c.180+3A>T p.Gln60ins*22
13 CLCN1 AR c.2680C>T p.Arg894* c.2680C>T p.Arg894*
20 CLCN1 AR c.1013G>A p.Arg338Gln c.1478C>A p.Ala493Glu
22 CLCN1 AR c.180+3A>T p.Gln60ins*22 c.180+3A>T p.Gln60ins*22
27 CLCN1 AD c.2680C>T p.Arg894* c.2564G>A p.Gly855Glu
29 CLCN1 AR c.2680C>T p.Arg894* c.1238T>G p.Phe413Cys
30 CLCN1 AD c.2680C>T p.Arg894*
31 CLCN1 AD c.937G>A p.Ala313Thr
32 CLCN1 AR c.2680C>T p.Arg894* c.696G>A p.Glu232Glu
33 CLCN1 AD c.2680C>T p.Arg894*
34 CLCN1 AD c.568G>A p.Gly190Arg
35 CLCN1 AR c.180+3A>T p.Gln60ins*22 c.2680C>T p.Arg894*
36 CLCN1 AR c.2680C>T p.Arg894* c.2680C>T p.Arg894*
39 CLCN1 AR c.501C>G p.Phe167Leu c.1437_1450del p.Ile479Ilefs*25
41 CLCN1 AR c.313C>T p.Arg105Cys c.501C>G p.Phe167Leu
42 CLCN1 AD c. 983C>T p.Thr328Ile
43 CLCN1 AR c.2401G>T p.Glu801* c.613G>A p.Glu205Lys
45 CLCN1 AR c.2114_2115het_insT p.Pro705ProfsX8
46 CLCN1 AR c.2926C>T p.Arg976X c.1655A>G p.Gln552Arg
47 CLCN1 AR c.2680C>T p.Arg894* c.1444_1449delGGA GGC p.Gly482_Gly483del
48 CLCN1 AD c.2680C>T p.Arg894*
49 CLCN1 AD c.2680C>T p.Arg894*
52 CLCN1 AD c.1445G>A p.Gly482Glu
53 CLCN1 AR c.2680C>T p.Arg894* c.2680C>T p.Arg894*
54 CLCN1 AD c.937G>A p.Ala313Thr
55 CLCN1 AR c.180+3A>T p.Gln60ins*22 c.2680C>T p.Arg894*
56 CLCN1 AR c.180+3A>T p.Gln60ins*22 c.1488G>T p.Arg496Ser
57 CLCN1 AR c.568G>A p.Gly190Arg c.1166+5G>A p.?
58 CLCN1 AR c.1238T>G p.Phe413Cys n.f n.f
60 CLCN1 AD c.1655A>G p.Gln552Arg
62 CLCN1 AD c.2680C>T p.Arg894*
63 CLCN1 AR c.2680C>T p.Arg894* c.1013G>A p.Arg338Gln
64 CLCN1 AD c.2680C>T p.Arg894*
65 CLCN1 AR c.979G>A p.Val327Ile c.1437_1450del p.Pro480Hisfs*24
66 CLCN1 AR c.2680C>T p.Arg894* c.2680C>T p.Arg894*
67 CLCN1 AD c.929C>T p.Thr310Met
70 CLCN1 AD c.2680C>T p.Arg894*
71 CLCN1 AR c.1649C>G p.Thr550Arg c.1649C>G p.Thr550Arg
72 CLCN1 AR c.180+3A>T p.Gln60ins*22 c.1488G>T p.Arg496Ser
73 CLCN1 AR c.2680C>T p.Arg894* c.2680C>T p.Arg894*
2 SCN4A AD c.2024G>A p. Arg675Gln
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is provided in Table 5, including the level of patients’ per-
ceived efficacy, documented by the treating physician.
Discussion
In this study, we depicted the clinical features of a large 
cohort of German patients with NDM thus adding valuable 
information to the few reported large cohorts of patients 
(Table 1) [12, 18, 21–27]. The core clinical features of our 
NDM cohort were mostly confirmatory of literature data, 
highlighting the significant clinical overlap between patients 
with NDM-CLCN1 and NDM-SCN4A. However, some new 
findings could be summarized. The age of onset could be 
collocated in the 1st to 2nd decade of life in most patients. 
Myotonia was the most prominent symptom, occurring more 
frequently in facial muscles in NDM-SCN4A and not sig-
nificantly but tendentially more frequently in the legs for 
NDM-CLCN1, muscle weakness tended to occur more fre-
quently in NDM-CLCN1. Myalgia was, immediately after 
myotonia, the most prevalent symptom during disease pro-
gression involving 52–57% of patients, without significant 
differences between NDM-CLCN1 and NDM-SCN4A. 
In the literature, the prevalence of pain in NDMs widely 
ranges from 28 to 53% in NDM-CLCN1 and from 56 to 
82% in NDM-SCN4A [12, 23, 24]. Some SCN4A mutations 
are known to be associated with myalgia (e.g., c.1333G>A, 
c.3917G>C, c.3466G>A), in our patients only 6/22 showed 
either c.1333G>A or the c.3917G>C mutation, thus explain-
ing only a minority of myalgic patients. The presence of pain 
is one of the major determinants of low quality of life in 
NDM patients [28] and needs to be properly monitored and 
treated. Some myotonia characteristics are considered more 
archetypal for one form or the other, as warm-up phenom-
enon and muscle hypertrophy usually points toward NDM-
CLCN1 and cold sensitivity toward NDM-SCN4A. In con-
trast, in our genetically confirmed cohort a more relevant 
clinical overlap was observed as the muscle hypertrophy, 
the warm-up phenomenon as well as grip- and percussion 
myotonia were frequently observed in both groups. Even the 
classic triggers were present in both NDM groups with an 
even higher prevalence of cold sensitivity for NDM-CLCN1 
patients. This finding is untypical as usually NDM-SCN4A 
patients refer a more prominent worsening of symptoms 
with cold temperatures, but it is well known that cold may 
worsen symptoms also in NDM-CLCN1 patients. Similar 
observations were also reported by Trivedi et al. [12] and 
should favor a genetic tandem analysis approach rather than 
a single gene sequencing. Extra-muscular manifestations are 
thought to be non-typical for NDM patients, even though the 
Table 4  (continued)
Pt. ID Gene Inheritance in 
the family*
Mutation 1 Mutation 1 Mutation 2 Mutation 2
7 SCN4A AD c.2111C>T p.Thr704Met
11 SCN4A AD c.4106C>A p.Thr1369Asn
14 SCN4A AD c.3917G>C p.Gly1306Ala
15 SCN4A AD c.1333G>T p.Val445Leu
16 SCN4A AD c.2078T>C p.Ile693Thr
17 SCN4A AD c.1333G>A p.Val445Met
18 SCN4A AD c.1333G>A p.Val445Met
19 SCN4A AD c.1333G>A p.Val445Met
21 SCN4A AD c.3917G>T p.Gly1306Val c.3917G>T p.Gly1306Val
23 SCN4A AD c.5113T>A p.Phe1705Ile
24 SCN4A AD c.2111C>T p.Thr704Met
26 SCN4A AD c.3917G>C p.Gly1306Ala
28 SCN4A AD c.3877G>A p.Val1293Ile
37 SCN4A AD c.4342C>T p.Arg1448Cys
40 SCN4A AD c.1333G>A p.Val445Met
51 SCN4A AD c.3893T>G p.Phe1298Cys
61 SCN4A AD c.3917G>T p.Gly1306Val
69 SCN4A AD c.2111C>T p.Thr704Met
74 SCN4A AD c.3917G>T p.Gly1306Val
75 SCN4A AD c.3917G>T p.Gly1306Val
76 SCN4A AD c.3917G>T p.Gly1306Val
*Some mutations in the CLCN1 gene have both a dominant or a recessive effect (e.g., p.R894*, p.A313T)
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role of SCN4A variants in causing cardiac arrhythmias and 
Brugada syndrome remains debated [29]. In our cohort, no 
patient with SCN4A mutations presented relevant cardiac 
involvement; on the other hand, six NDM-CLCN1 patients 
had cardiac arrhythmias or conduction defects, requiring the 
implantation of a pacemaker in three patients. In particular, 
patient 65 required pacemaker implantation at age 30 years 
and has a positive family history of dilative cardiomyopathy 
documented in her father’s and brother’s medical history, the 
latter also presented with a NDM-CLCN1-myotonia. Given 
the autosomal recessive nature of the two known pathogenic 
CLCN1 gene mutations in this patient (c.180+3A>T and 
c.1488G>T), we interpret this case as an obvious double-
trouble situation. The ClC-1 channel is mainly expressed in 
the skeletal muscle and only at limited levels in smooth mus-
cle, kidney, heart, liver, and CNS [30, 31]. Since no extra-
muscular and especially cardiac manifestations of NDM are 
reported in other NDM-CLCN1 cohorts so far and given 
the low number of patients with cardiac arrhythmias in our 
cohort, a causal relation between CLCN1 mutation and car-
diac manifestations stays unlikely. However, NDM patients 
must undergo regular cardiac evaluation as the intake of 
anti-myotonic drugs can unmask latent and potentially life-
threatening arrhythmias.
The mean diagnostic delay of this cohort was quite long 
(16.6 ± 12.2 years), even for a rare disease. Similar results 
were however reported by Baumann et al. (18 ± 14 years) 
and Trip et al. (12.0 ± 10.4 years) [21, 24]. From our results, 
it appears that the longest delay occurred between the onset 
of symptoms and first EMG performed (12.6 ± 10.7 years). 
This suggests that patients are often not immediately referred 
to a neurologist, being misdiagnosed as fibromyalgia or 
chronic pain syndrome; in other cases, patients with mildly 
pronounced symptoms, negative family history, normal CK 
will not seek immediate medical consultation. A normal CK 
was found in 39.6% of our patients, thus this should not pre-
vent the suspicion of NDM or the referral to a neurologist. In 
the current German guidelines on NDM, the measurement of 
CK is a mandatory part of the diagnostic testing and is stated 
to be no more than 5 × upper normal limits (UNL) for NDM-
CLCN1 and often more than twice the UNL for SCN4A-
myotonias [11]. In some patients with SCN4A-myotonia, we 
observed CK elevation up to 1100 U/L. These values may 
have been influenced by various factors, such as physical 
activity on the previous day. The EMG detected myotonic 
runs in 89% of NDM-CLCN1 and 80% of NDM-SCN4A 
patients without provocative cold test and confirmed to be 
the most valuable diagnostic tool for the identification of 
NDM patients and indication of genetic testing.
In our NDM-CLCN1 cohort, the common mutation 
c.2680C>T (p.Arg894*) was found in 50%. This typical 
Thomsen CLCN1 mutation, confirmed in the original Thom-
sen family from Northern Germany, is also frequently found 
in Northern Scandinavia, Russia, Denmark and to a lesser 
Table 5  Anti-myotonic treatment in NDMs
a Anti-myotonic drugs with perceived best efficacy; 1 = excellent, 2 = good, 3 = poor
b One patient received up to 1200 mg with major side effects
Drug Dose (mg) N (total) NDM-CLCN1% NDM-SCN4A% Patients’ perceived efficacy (mean value 
score)
n NDM-CLCN1 NDM-SCN4A
Commonly used anti-myotonic drugs
 Carbamazepine 100–1600 19 78.9 21.1 12 2.9 3
 Flecainide 50–300 16 87.5 12.5 14 2.5 3
 Mexiletinea 200-600b 15 80 20 10 1.89 2
 Lamotriginea 50–300 8 75 25 6 2.25 2
 Acetazolamide 125–500 6 33.3 66.7 3 n.a 2.3
 Phenytoin 100–300 5 80 20 3 3 3
 Mexiletine ret.a 360–720 4 100 0 4 1.3 1
 Propafenone 150–450 2 100 0 2 3 n.a
Other drugs with potential anti-myotonic effect
 Tolperisone 50–450 18 83.3 16.7 13 2.9 3
 Gabapentin 100–3600 11 72.7 27.3 8 2.8 2.7
 Methocarbamol 750–4500 9 77.8 22.2 8 2.8 2.5
 Pregabalin 150–600 5 80 20 n.a n.a n.a
 Baclofen 10–75 2 100 0 n.a n.a n.a
 Cannabinoid/THC 20.58–41.16/2.2–6.02 2 100 0 2 2 n.a
 Oxcarbazepine 35–150 1 100 0 n.a n.a n.a
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extent in The Netherlands, Spain, and Italy [32, 33]. It still 
has a high prevalence in northern Europe. Other mutations 
were most frequent in Spain (c.180+3A>T), the Netherlands 
(c.1238T>G, p.F413C), and Italy (c.501C>G, p.F167L) [25, 
34–36]. In our study, no clear genotype–phenotype cor-
relations could be identified, this might be also related to 
the several different mutations that our patients presented 
throughout the genes. Some previous functional studies have 
demonstrated how the location of the mutations in the differ-
ent channel domains deeply influences the clinical severity 
and response to therapy producing major differences among 
patients sharing the same gene defect but different muta-
tions. On the other hand, different phenotypes have also been 
described in patients with the same mutation, suggesting that 
modifier genes and environmental condition might influence 
the clinical features of individual patients [37, 38].
We found 12 novel genetic variants. Although we did not 
perform functional studies, we included some class 3 muta-
tions that were highly suggestive of being pathogenic due to 
investigation of family members, indicative clinical symp-
toms and the evidence of EMG myotonia. Very interestingly, 
patient 21 displayed the dominant c.3917G>T mutation on 
both alleles. This change from glycine to valine is known 
to cause moderate to severe myotonia [39] and this patient 
displayed earlier and more severe symptoms compared to 
other affected family members.
The main differential diagnosis of NDM were dystrophic 
myotonias, with a national biased approach, like myotonic 
dystrophy type 2 being tested slightly more frequently than 
myotonic dystrophy type 1 in our sample. Other genes exam-
ined in these NDM patients were CAV3, ATP2A1 (Brody 
disease) and HINT1 (hereditary neuromyotonia with axonal 
neuropathy). Since 2010 next-generation sequencing can 
be used in the clinical setting in Germany. Therefore, we 
wanted to examine whether this new sequencing technique 
reduced the diagnostic delay of NDMs. However, no signifi-
cant differences were observed for the diagnostic delay in 
patients diagnosed before and after 2010. Probably because 
even before 2010 tandem analysis of CLCN1 and SCN4A 
was commonly conducted.
The effective symptomatic treatment of NDM remains 
a challenge. At their last follow-up visit, about 50% of 
our patients (44.7% NDM-CLCN1, 63.6% NDM-SCN4A) 
were not taking any anti-myotonic therapy. Trivedi et al. 
reported the use of anti-myotonic medication in 60.6% 
of patients, Dupré et al. in 41% of recessive (36% with 
significant improvement), 0% of dominant NDM-CLCN1 
patients and 43% of NDM-SCN4A patients. As described 
by Dupré et al., phenytoin and gabapentin were most effec-
tive in patients with recessive CLCN1-myotonia, while 
mexiletine and carbamazepine were most effective in 
patients with SCN4A-myotonia [12, 22]. The most fre-
quently used anti-myotonic drugs were carbamazepine, 
flecainide, mexiletine and lamotrigine in this order of fre-
quency. Flecainide and mexiletine are the drugs of first 
choice according to the current German guidelines, carba-
mazepine was more used in the past and lamotrigine more 
recently after the clinical study by Anderson et al. [11, 
16] Patients rated mexiletine, and lamotrigine as the most 
effective therapies, in accordance with recent RCTs [15, 
16], whereas other medications were mainly considered as 
not satisfactory. This is also confirmed by the high number 
of tested anti-myotonic drugs (up to 11 different drugs). 
The good efficacy of phenytoin/gabapentin in recessive 
CLCN1-myotonia and carbamazepine and mexiletine 
in SCN4A-myotonia reported by Dupré et al. was, with 
exception of mexiletine, not observed in our cohort [22]. 
Our data however, lack information regarding the duration 
of anti-myotonic drug intake and patients’ compliance, 
which may impact the evaluation of drug efficacy.
The limitation of our study is its retrospective design. 
The collection of information has been likely affected by the 
accuracy of different physicians in record keeping. Despite 
this, the strength of our study lies in a large number of genet-
ically confirmed patients, and the opportunity of a direct 
comparison of patients with either a CLCN1 or a SCN4A 
gene mutation in one single highly specialized neuromus-
cular center over 25 years.
In summary, this study highlights the clinical, genetic 
and therapeutic challenges related to the diagnosis and man-
agement of NDM patients and unmet needs are the lack of 
follow-up studies of large cohorts with reliable assessments 
of disease progression and treatment efficacy.
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